stock reaction uf data overdon
 think sell-off myov share morn overdon releas relugolix phase uterin fibroid data ith
trial meet primari potenti differenti secondari endpoint ell show ing excel safeti profil
 continu think relugolix compar profil abbv/nbix elagolix ill find place larg untap omen
health market given previou derisk data indic takeda phase studi myovant phase think
risk/rew ard split skew ed dow nside go data investor sell new still view today data
posit myovant ith data expect follow ed nda file continu see upsid stock
maintain ow pt
pushback focus benefit placebo respond rate investor feedback focus respond rate compar ith
placebo vs percentag point differ although compar arm elagolix trial low er placebo
respond rate larger differ betw een arm vs percentag point differ elari vs
percentag point differ elaris-uf ould highlight inher variabl placebo respond rate
even treatment arm respons rate duplic elari studi given natur data collect endpoint
 think percentag point spread may meaning differ seen elagolix
manag focu bleed reduct benefit spoke ith manag morn ho emphas respond rate
import endpoint regulatori purpos averag percent reduct bleed meaning measur
benefit patient like receiv hile compar measur elagolix trial manag note
result seen highli clinic meaning posit relugolix ell ith regul ell marketplac
manag also highlight physician feedback indic demand confid consist patient benefit simpl easi
prescrib dose regimen hich particularli import patient suffer uf endometriosi
relugolix potenti differenti marketplac addit efficaci hich think par ith elagolix relugolix
also sever potenti differenti attribut could drive uptak pain endpoint uniqu uf
measur competitor pain anoth import symptom uf potenti pain benefit label could help set
relugolix apart note takeda perform separ phase trial pain hich includ japanes label myovant ill also
abl use data studi nda submiss
coverag myovant women health space
myov thought posit uterin fibroid data
myovant scienc ltd upgrad overw eight pt
slide omen health survey see link
 biopharmaceut omen health survey posit abbv/nbix
myov take present
abbv/nbix thought orilissa elagolix approv
give us call ith question geoff greg olivia jason scott
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
master limit partnership mlp pass-through entiti structur publicli list partnership tax purpos
distribut unit holder may treat return princip investor consult ow tax advisor
invest unit
valuat methodolog valu use discount cash flow analysi assum impli intrins
valu per share
risk may imped achiev barclay research valuat price biosimilar make greater
headw ay market cannib share humira could potenti face addit dow nside risk humira current
compris total sale declin drug outlook could sever impact earn addit hcv
portfolio could fail captur share exist competit also imbruvica could limit label expans oncolog
grow th may meet expect pipelin failur could also drive dow nside
rate price target histori
prior intra-day chang may publish rate secur equal eight
adjust price target
histor stock price price target may adjust stock split dividend
valuat methodolog price target per share base npv analysi forecast risk adjust sale
relugolix assum patent expir ith year hatch-w axman exclus extens assum
termin valu includ sale omen health indic uf em line ith biotech similar size
development stage assum discount rate product launch year follow ing plan read out
phase trial uterin fibroid endometriosi base assumpt deriv valuat compris
relugolix us sale eu sale omen health net cash
risk may imped achiev barclay research valuat price clinic development
risk myovant lead asset relugolix mid-stag develop uterin fibroid uf endometriosi advanc
prostat cancer despit encourag posit phase data indic guarante pivot phase studi
 ill demonstr posit clinic meaning outcom failur indic especi uterin fibroid
market risk smid-cap biotechnolog histor volatil relugolix light catalyst calendar balanc
year hich may exagger dynam investor may opt put capit ork outsid myov share near
term hich may neg impact compani share
regulatori risk nda file relugolix uf endometriosi expect late assum posit phase
data asset ould expect indic grant approv ever fda may approv agent
agenc may fail ithin expect timelin delay inabl gain approv ould significantli pressur myov
commerci risk myovant plan launch relugolix us europ omen potenti
advanc prostat cancer myovant experi commerci drug ould need build commerci
infrastructur hich could prove challeng prevent myovant maxim drug commerci opportun failur
relugolix gain meaning market share compet effect could pressur myov share
reimburs risk relugolix develop treatment endometriosi uterin fibroid advanc prostat
cancer develop current behind drug ithin class elagolix could gain signific market share approv
addit gener leuprolid acet avail indic current sell cost brand lupron
 hile believ relugolix offer meaning differenti payor may requir use gener lupron ahead relugolix use
mechan limit drug penetr market durat includ mandat use elagolix vs relugolix
rate price target histori
histor stock price price target may adjust stock split dividend
valuat methodolog valuat price target base npv analysi forecast sale elagolix
elagolix assum tier royalti rate zero termin valu discount rate also includ
risk adjust ou sale elagolix ingrezza model us sale tardiv dyskinesia base assumpt
deriv valuat compris elagolix royalti ingrezza sh
opicapon mileston net cash
risk may imped achiev barclay research valuat price clinic risk failur
opicapon ould also neg impact neurocrin share price
regulatori risk nda review elagolix uf expect guarante elagolix ill approv delay
inabl gain approv ould significantli pressur share
risk neurocrin lead asset elagolix partner ith hich respons develop commerci
market cost neurocrin also entitl royalti sale elagolix unabl success execut
launch plan neurocrin share ill like neg impact
commerci risk neurocrin current ow ns right ingrezza launch drug us neurocrin
experi commerci drug ould need continu build commerci infrastructur hich could prove
challeng prevent neurocrin maxim drug commerci opportun competit relugolix could also
significantli impact commerci potenti elagolix failur ingrezza gain meaning market share compet effect
reimburs risk elagolix develop treatment endometriosi uterin fibroid gener key
competitor lupron avail sell cost brand lupron hile believ elagolix offer meaning
differenti guarante payor ill requir use gener lupron ahead elagolix use mechan
limit drug penetr market durat similarli guarante ingrezza ill reimburs
payor ill introduc hurdl use hich could neg impact compani revenu
rate price target histori
prior intra-day chang may publish rate secur overw eight
adjust price target
histor stock price price target may adjust stock split dividend
price sourc refinitiv last avail close price relev trade market unless anoth time sourc
indic
